Global law firm Baker McKenzie advised Galapagos, a Belgian headquartered biotechnology company listed on Nasdaq and Euronext, on its acquisition of two companies, CellPoint and AboundBio. CellPoint, a Netherlands headquartered, privately held biotechnology company dedicated to developing CAR-T therapies at the point-of-care, was acquired for an upfront amount of €125 million, with milestone payments up to €100 million. AboundBio, a U.S. headquartered, privately held biotechnology company focused on developing innovative antibody-based biological therapeutics for cancers of unmet medical need, was acquired for an amount of $14million. The transactions have been fully executed and the acquisitions were consummated on 21 June 2022. Both acquisitions will accelerate Galapagos' access to next generation cell therapies, significantly broaden their portfolio and will serve to position Galapagos in the next-generation cancer therapy market.
The Baker McKenzie team that advised on the CellPoint transaction was led by Rebecca Kuijpers-Zimmerman (Amsterdam) and Roel Meers (Brussels), supported by Casper Henschen (Amsterdam), Oren Livne (New York) and Els Janssens (Belgium). The Baker McKenzie team that advised on the AboundBio transaction was led by Olivia Tyrrell (Chicago) and Michelle Heisner (New York).
Baker McKenzie is a transactional powerhouse providing commercially-focused, end to end legal advice to maximize deal certainty and secure the intended value of transactions. Our 2,500 transactional lawyers combine money market sophistication with local market excellence. We lead on major transactions and the combination of deep sector expertise and our ability to work seamlessly across each of the countries where we operate, means we add unique value in shaping, negotiating and closing the deal. As one of the first law firms to advise life sciences companies on their global expansion 60 years ago, our deep industry knowledge is rooted in our corporate DNA. Our impressive group, recognized by various legal rankings including LMG and Chambers, is comprised by over 800 lawyers in 467 countries, including in the top 10 largest markets in the world.
The Baker McKenzie team that advised on the CellPoint transaction was led by Rebecca Kuijpers-Zimmerman (Amsterdam) and Roel Meers (Brussels), supported by Casper Henschen (Amsterdam), Oren Livne (New York) and Els Janssens (Belgium). The Baker McKenzie team that advised on the AboundBio transaction was led by Olivia Tyrrell (Chicago) and Michelle Heisner (New York).
Baker McKenzie is a transactional powerhouse providing commercially-focused, end to end legal advice to maximize deal certainty and secure the intended value of transactions. Our 2,500 transactional lawyers combine money market sophistication with local market excellence. We lead on major transactions and the combination of deep sector expertise and our ability to work seamlessly across each of the countries where we operate, means we add unique value in shaping, negotiating and closing the deal. As one of the first law firms to advise life sciences companies on their global expansion 60 years ago, our deep industry knowledge is rooted in our corporate DNA. Our impressive group, recognized by various legal rankings including LMG and Chambers, is comprised by over 800 lawyers in 467 countries, including in the top 10 largest markets in the world.
Explore Our Newsroom